CellCyte Genetics to Present at 2008 San Francisco RedChip Small-Cap Investor Conference

BOTHELL, Wash., June 4 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation's (CellCyte) (OTC Bulletin Board: CCYG) President and CEO, Gary A. Reys, will present at the 2008 San Francisco RedChip Small-Cap Investor Conference on Thursday, June 5, at 10:35 AM Pacific Daylight Time at the Palace Hotel in San Francisco. In addition, CellCyte will have a booth at the conference at which they will have a prototype demonstration of the Company's cell expansion bioreactor.

The presentation will be Web cast live with slides and archived for replay after the presentation at: http://www.redchip.com/visibility/conferencePages/SanFran2008/conferenceMain.a sp?page=webcast

About CellCyte Genetics

CellCyte Genetics Corporation is a biotechnology company engaged in the discovery, development and commercialization of stem cell enabling therapeutic products. CellCyte is developing products to allow more efficient delivery and increased retention of adult stem cells to diseased organs, such as the heart. The goal of these therapies is to increase the number of stem cells delivered to a damaged organ, thereby markedly increasing organ healing and functional restoration. The Company's lead product in development, CCG-TH30, is designed to send autologous bone marrow-derived (adult) stem cells to the heart of patients after a heart attack.

SOURCE CellCyte Genetics Corporation

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.